LCZ696 200 mg BID + Enalapril 10 mg BID
Phase 3Terminated 0 watching 0 views this week
0
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heart Failure With Reduced Ejection Fraction
Conditions
Heart Failure With Reduced Ejection Fraction
Trial Timeline
Dec 1, 2009 → May 1, 2014
NCT ID
NCT01035255About LCZ696 200 mg BID + Enalapril 10 mg BID
LCZ696 200 mg BID + Enalapril 10 mg BID is a phase 3 stage product being developed by Novartis for Heart Failure With Reduced Ejection Fraction. The current trial status is terminated. This product is registered under clinical trial identifier NCT01035255. Target conditions include Heart Failure With Reduced Ejection Fraction.
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01035255 | Phase 3 | Terminated |
Competing Products
20 competing products in Heart Failure With Reduced Ejection Fraction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |